Business News • PR NewsWire • ImaginAb and Roche have entered a clinical trial supply agreement for provision of atezolizumab (Tecentriq®)1 to Non-Small Cell Lung Cancer Patients Enrolled in ImaginAb's iPREDICT Phase IIb Study

ImaginAb and Roche have entered a clinical trial supply agreement for provision of atezolizumab (Tecentriq®)1 to Non-Small Cell Lung Cancer Patients Enrolled in ImaginAb's iPREDICT Phase IIb Study

ImaginAb and Roche have entered a clinical trial supply agreement for provision of atezolizumab (Tecentriq®)1 to Non-Small Cell Lung Cancer Patients Enrolled in ImaginAb's iPREDICT Phase IIb Study

LOS ANGELES, June 8, 2022 /PRNewswire/ -- ImaginAb Inc., a market leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT), is pleased to announce that Roche has agreed to provide US approved...

View More : https://www.prnewswire.com:443/news-releases/imaginab-and-roche-have-entered-a-clinical-trial-supply-agreement-for-provi...

Releted News by prnewswire

Gaming Innovation Group signs a head of terms agreement with Crab Sports in Maryland

Cufflinks Market Size to Grow by USD 1.35 billion | Find Future Trends, Analysis, and Insights | Technavio

Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers

ImaginAb and Roche have entered a clinical trial supply agreement for provision of atezolizumab (Tecentriq®)1 to Non-Small Cell Lung Cancer Patients Enrolled in ImaginAb's iPREDICT Phase IIb Study

DNS Abuse Institute Launches NetBeacon: First Ever Centralized DNS Abuse Reporting Service

True Cost of Fraud Soars as Cybercriminals Diversify

Chung Mong-won, président du groupe Halla, est intronisé au Temple de la Renommée de l'IIHF